Contemporary Strategies for Comorbid Obesity, Hypertension, and Chronic Heart Failure in Primary Care: An Evidence-Based Perspective

Background: The growing prevalence of comorbid obesity, hypertension, and chronic heart failure (CHF) represents a significant public health challenge, particularly in primary care. These conditions create a complex clinical triad that exacerbates cardiovascular risk, worsens prognosis, and increases healthcare burdens. Understanding the multifaceted pathophysiology and adopting evidence-based strategies is essential for improving patient outcomes. Methods and Materials: This study synthesized data from clinical guidelines, systematic reviews, meta-analyses, and peer-reviewed journal articles, focusing on evidence-based management of obesity, hypertension, and CHF. Sources included PubMed, Cochrane Library, NICE guidelines, and studies on advanced diagnostics, pathophysiology, and emerging therapeutic approaches such as SGLT2 inhibitors and GLP-1 receptor agonists. Results: The findings highlight the critical role of neurohormonal dysregulation, inflammation, and metabolic derangements in the development of comorbidities. Pharmacological interventions like SGLT2 inhibitors and GLP-1 receptor agonists demonstrated significant cardiovascular and renal benefits, while personalized lifestyle modifications, including diet and tailored exercise regimens, improved outcomes. Furthermore, novel biomarkers and genetic insights enable precision risk stratification and early intervention strategies in primary care. Conclusion: Integrated, multidisciplinary approaches are essential for managing comorbid obesity, hypertension, and CHF. Combining personalized pharmacotherapy with innovative diagnostics and lifestyle interventions optimizes clinical outcomes, reduces disease progression, and enhances quality of life. Addressing barriers in primary care will further refine the management of these high-risk patients.